menu
    • menu
    [{"orgOrder":0,"company":"Piramal Critical Care","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Piramal Critical Care","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Piramal Critical Care \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Critical Care \/ Inapplicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endo International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"PolyPid","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Powder","sponsorNew":"PolyPid \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"NanoSHIFT","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase 13 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Massachusetts General Hospital \/ NanoSHIFT","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ NanoSHIFT"},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSIDS Research Foundation \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Medical Corps, Israel Defense Force \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Doxycyclinum [INN-Latin]

    Menu

    Doxycyclinum [INN-Latin]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S.

                            Details : Oracea-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

                            Product Name : Oracea-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolyPid Completes Enrollment in Phase 3 SHIELD II Trial of D-PLEX100

                            Details : D-PLEX100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.

                            Product Name : D-Plex

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endo International

                            Ireland arrow
                            CPhI Korea
                            Not Confirmed

                            Endo International

                            Ireland arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Endo Launches Doxycycline for Injection, USP

                            Details : Doxy 100-Generic (doxycycline) is a tetracycline class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medical Corps, Israel Defense Force

                            Country arrow
                            CPhI Korea
                            Not Confirmed

                            Medical Corps, Israel Defense Force

                            Country arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Postexposure Prophylaxis With Single Dose Doxycycline for the Prevention of Tick-borne Relapsing Fever

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Piramal Critical Care

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            Piramal Critical Care

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Piramal Critical Care Announces the U.S. Launch of Doxycycline for Injection, USP

                            Details : Doxycycline for Injection, USP is a Protein 30S ribosomal subunit inhibitor, which is used for prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

                            Product Name : Doxycycline-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 16, 2023

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Massachusetts General Hospital

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            Massachusetts General Hospital

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : NanoSHIFT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigation of Laser Assisted Drug Delivery of NanoDOX®

                            Details : Undisclosed

                            Product Name : NanoDOX

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : NanoSHIFT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MSIDS Research Foundation

                            Country arrow
                            CPhI Korea
                            Not Confirmed

                            MSIDS Research Foundation

                            Country arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MSIDS Research Foundation Study Finds That Leprosy Drugs Provide Potential Cure for Chronic Lyme Disease

                            Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 28, 2020

                            Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zydus Lifesciences

                            India arrow
                            CPhI Korea
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zydus Receives USFDA SANDA Approval for Doxycycline Injection

                            Details : Zydus Cadila has received approval for its supplemental Abbreviated New Drug Application (SANDA) for Doxycycline Injection USP, 100 mg/Vial from the US FDA.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            July 16, 2020

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (S...

                            Details : Undisclosed

                            Product Name : D-PLEX

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 02, 2020

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed

                            PolyPid

                            Israel arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

                            Details : Undisclosed

                            Product Name : D-PLEX

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Doxycycline

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth